Although rapalog therapy causes tumor reduction in lymphangioleiomyomatosis (LAM) and angiomyolipoma (AML), each due predominantly to inactivating TSC2 mutations, there was a dramatic tumor regrowth after treatment cessation (15). This evidence concerns the gene TSC2 and lymphangioleiomyomatosis.